OCT Medical Devices 2025: AI innovation to increase cybersecurity risks in 2025
The growing sophistication of medical devices make it likely that 2025 will be another challenging year for cybersecurity and medical …
Post
-
-
RFK Jr. denies being anti-vaccine during intense Senate confirmation
US President Donald Trump’s candidate for Secretary of Health and Human Service (HHS), Robert F Kennedy Jr. has been grilled …
-
Ryght AI and CRSA partner to improve cancer trials for patients in South Australia
US-based clinical research software company Ryght AI has partnered with Cancer Research South Australia (CRSA) to advance cancer clinical trials …
-
Decentralisation boosts diversity in trials, study finds
Decentralisation in clinical trials could boost representation for more diverse demographic groups, a study has found. Research unveiled by the Tufts …
-
OCT Medical Devices 2025: biggest regulatory requirement issues ‘start at the site level’
The challenges in meeting regulatory requirements during a clinical investigation often start at the site level, and strong communication and …
-
Decentralisation boosts diversity in trials, study finds
Decentralisation in clinical trials could boost representation for more diverse demographic groups, a study has found. Research unveiled by the Tufts …
-
OCT Medical Devices 2025: biggest regulatory requirement issues ‘start at the site level’
The challenges in meeting regulatory requirements during a clinical investigation often start at the site level, and strong communication and …
-
Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints
US-based biopharmaceutical company Kashiv Biosciences has reported that a Phase I trial of its 125mg/mL pre-filled syringe injection, KSHB002, has …
-
OCT Medical Devices 2025: patient shifts and tech driving healthcare innovation
Shifting patient demographics and the rise of AI-based technology and wearables are emerging as key drivers of innovation in the …
-
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial
US-based pharmaceutical company 60 Degrees Pharmaceuticals has received approval from the investigational review board (IRB) for a Phase II trial …
-
Allakos cuts 75% of workforce after chronic hives trial failure
Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme following …
-
ITM’s radiotherapeutic beats out standard-of-care in Phase III trial
ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs) …
-
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
Genentech Therapeutics’s Phase III trial of Itovebi in patients with certain types of metastatic breast cancer has met the gold …
-
Akero’s cirrhosis treatment shows promise in Phase IIb study
Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) in individuals …
-
OCT Medical Devices 2025: European AI Act compliance ‘not a cause for panic’
For healthcare firms involved in the spaces of software-as-a-medical-device (SaMD), or digital devices and artificial intelligence (AI) devices, compliance with …
